Sweta Tandra1, Matthew M Yeh2, Elizabeth M Brunt3, Raj Vuppalanchi1, Oscar W Cummings1, Aynur Ünalp-Arida4, Laura A Wilson4, Naga Chalasani5. 1. Indiana University School of Medicine, Indianapolis, IN, USA. 2. University of Washington School of Medicine, Department of Pathology, Seattle, WA, USA. 3. Washington University School of Medicine, Department of Pathology and Immunology, St. Louis, MO, USA. 4. Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 5. Indiana University School of Medicine, Indianapolis, IN, USA. Electronic address: nchalasa@iupui.edu.
Abstract
BACKGROUND & AIMS: Liver biopsies from patients with nonalcoholic fatty liver disease (NAFLD) sometimes exhibit non-zonal aggregates of hepatocytes with microvesicular steatosis, but its prevalence and significance are unclear. In this study, we have evaluated the frequency of microvesicular steatosis and assessed its association with histological markers of disease severity in a large sample of NAFLD liver biopsies. METHODS: Liver biopsies from a large cohort of adults who participated in two studies conducted by the NASH Clinical Research Network (NASH CRN) were included in this cross-sectional study. Liver histology was assessed centrally and various histological features scored in a systematic fashion. The relationship between microvesicular steatosis and various histological features that characterize NAFLD was tested by multiple logistic regression, after controlling for age, gender, race, body mass index, and diabetes. RESULTS: Among 1022 liver biopsies included, 102 (10%) had microvesicular steatosis. No demographic differences were noted between patients with or without microvesicular steatosis. The presence of microvesicular steatosis was associated with higher grades of steatosis (p<0.001), ballooning cell injury (p<0.001), presence of Mallory-Denk bodies (p<0.007), presence of megamitochondria (p<0.0001), higher NAS scores (p<0.0001), more advanced fibrosis (p<0.0001), and diagnosis of borderline or definite NASH (p<0.0001). CONCLUSIONS: Microvesicular steatosis correlates with more advanced histology of NAFLD. Longitudinal studies are needed to address the role of microvesicular steatosis in mediating cellular injury and disease progression in NAFLD.
BACKGROUND & AIMS: Liver biopsies from patients with nonalcoholic fatty liver disease (NAFLD) sometimes exhibit non-zonal aggregates of hepatocytes with microvesicular steatosis, but its prevalence and significance are unclear. In this study, we have evaluated the frequency of microvesicular steatosis and assessed its association with histological markers of disease severity in a large sample of NAFLD liver biopsies. METHODS: Liver biopsies from a large cohort of adults who participated in two studies conducted by the NASH Clinical Research Network (NASH CRN) were included in this cross-sectional study. Liver histology was assessed centrally and various histological features scored in a systematic fashion. The relationship between microvesicular steatosis and various histological features that characterize NAFLD was tested by multiple logistic regression, after controlling for age, gender, race, body mass index, and diabetes. RESULTS: Among 1022 liver biopsies included, 102 (10%) had microvesicular steatosis. No demographic differences were noted between patients with or without microvesicular steatosis. The presence of microvesicular steatosis was associated with higher grades of steatosis (p<0.001), ballooning cell injury (p<0.001), presence of Mallory-Denk bodies (p<0.007), presence of megamitochondria (p<0.0001), higher NAS scores (p<0.0001), more advanced fibrosis (p<0.0001), and diagnosis of borderline or definite NASH (p<0.0001). CONCLUSIONS:Microvesicular steatosis correlates with more advanced histology of NAFLD. Longitudinal studies are needed to address the role of microvesicular steatosis in mediating cellular injury and disease progression in NAFLD.
Authors: Pontus Boström; Mikael Rutberg; Johanna Ericsson; Peter Holmdahl; Linda Andersson; Michael A Frohman; Jan Borén; Sven-Olof Olofsson Journal: Arterioscler Thromb Vasc Biol Date: 2005-07-28 Impact factor: 8.311
Authors: David E Kleiner; Elizabeth M Brunt; Mark Van Natta; Cynthia Behling; Melissa J Contos; Oscar W Cummings; Linda D Ferrell; Yao-Chang Liu; Michael S Torbenson; Aynur Unalp-Arida; Matthew Yeh; Arthur J McCullough; Arun J Sanyal Journal: Hepatology Date: 2005-06 Impact factor: 17.425
Authors: Naga Chalasani; Laura Wilson; David E Kleiner; Oscar W Cummings; Elizabeth M Brunt; Aynur Unalp Journal: J Hepatol Date: 2008-02-12 Impact factor: 25.083
Authors: Jie Yan; Yang Yu; Jeon Woong Kang; Zhi Yang Tam; Shuoyu Xu; Eliza Li Shan Fong; Surya Pratap Singh; Ziwei Song; Lisa Tucker-Kellogg; Peter T C So; Hanry Yu Journal: J Biophotonics Date: 2017-06-21 Impact factor: 3.207
Authors: Sofia de Oliveira; Ruth A Houseright; Alyssa L Graves; Netta Golenberg; Benjamin G Korte; Veronika Miskolci; Anna Huttenlocher Journal: J Hepatol Date: 2018-12-18 Impact factor: 25.083
Authors: Jurgen H Runge; Pieter J Bakker; Ingrid C Gaemers; Joanne Verheij; Theo B M Hakvoort; Roelof Ottenhoff; Aart J Nederveen; Jaap Stoker Journal: MAGMA Date: 2013-11-01 Impact factor: 2.310
Authors: Joanna M Lotowska; Maria E Sobaniec-Lotowska; Sylwia B Bockowska; Dariusz M Lebensztejn Journal: World J Gastroenterol Date: 2014-04-21 Impact factor: 5.742
Authors: Anna K Kopec; Sara R Abrahams; Sherry Thornton; Joseph S Palumbo; Eric S Mullins; Senad Divanovic; Hartmut Weiler; A Phillip Owens; Nigel Mackman; Ashley Goss; Joanne van Ryn; James P Luyendyk; Matthew J Flick Journal: J Clin Invest Date: 2017-07-24 Impact factor: 14.808
Authors: David A Cappel; Stanisław Deja; João A G Duarte; Blanka Kucejova; Melissa Iñigo; Justin A Fletcher; Xiaorong Fu; Eric D Berglund; Tiemin Liu; Joel K Elmquist; Suntrea Hammer; Prashant Mishra; Jeffrey D Browning; Shawn C Burgess Journal: Cell Metab Date: 2019-04-18 Impact factor: 27.287